Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block.
about
hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.New potential binding determinant for hERG channel inhibitors.Role of the pH in state-dependent blockade of hERG currents.Drug trapping in hERG K+ channels: (not) a matter of drug size?Getting to the heart of hERG K(+) channel gating.In silico prediction of hERG inhibition.Compilation and physicochemical classification analysis of a diverse hERG inhibition database.Development of Safe Drugs: The hERG Challenge.Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic CardiotoxicityInteractions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.Computational Tool for Fast in silico Evaluation of hERG K+ Channel Affinity.The Basis for Low-affinity hERG Potassium Channel Block by Sotalol.Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.A Continuum Poisson-Boltzmann Model for Membrane Channel Proteins.In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.Structural implications of hERG K+ channel block by a high-affinity minimally structured blocker.Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities
P2860
Q36085808-C7F1F85A-FEA8-4C7C-811D-5FEBE4E5CEBEQ36789993-7384DF47-6806-4BCA-BF55-B6BFC173D0F9Q37330268-D16881C3-8600-4DC1-9A1E-6184C8938939Q37626136-7A4B2520-FED7-4586-AB5A-C38122BDB498Q38395148-C376B01D-F17A-4958-B066-860720C6C833Q38447279-F044D26D-2071-44F4-AEAE-78C9E1A1DCCFQ39248121-7AD64E1B-3685-4D21-9BC8-196C5C55D9E3Q39280559-BE9FBAA3-FDC4-4401-B650-265D1C7799D6Q41684522-9EBCBAFA-382C-4B21-B2D5-C7FAD739A9EDQ42173245-A321E506-2064-4860-B39D-A5241CFB8FE1Q42290305-4C97DE43-5BB0-4235-BA92-AABC246796ABQ42699631-EB0EE656-4928-4CBD-8BBB-0F10B5565CBEQ42768918-B718BDA6-37AF-41F4-9E6C-42F84C425AE0Q43070404-0BE608BD-8567-4B78-A2B9-92F2E310056AQ47098646-9EE8564A-BF40-4596-899E-92654885B0E6Q50627316-57BDD8A4-1347-4198-9795-89438FD81070Q51157253-0754643B-8E15-4031-8F31-27DD5F4C5878Q53837170-976BAAA2-5099-471B-9DA2-8D45053FC422Q58553697-56E4F8B4-8F72-49F6-9EDB-AA5907908251
P2860
Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Assessing hERG pore models as ...... in the context of drug block.
@en
type
label
Assessing hERG pore models as ...... in the context of drug block.
@en
prefLabel
Assessing hERG pore models as ...... in the context of drug block.
@en
P2093
P2860
P356
P1476
Assessing hERG pore models as ...... in the context of drug block.
@en
P2093
Charlotte K Colenso
Christopher E Dempsey
Dominic Wright
Jules C Hancox
Richard B Sessions
P2860
P304
P356
10.1021/CI400707H
P577
2014-02-06T00:00:00Z